Immutep Limited (IMMP), an Australian biotech company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces it participated in two post presentations at ASCO Chicago.
TACT-001 (Two ACTive Immunotherapies)
A Phase II clinical trial with both Immutep in collaboration with Merck. The multi-center Phase II clinical trial is evaluating the combination of efti with Merck’s Keytruda in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
Two additional Stratums of INSIGHT Trial
This prospective investigator initiated Phase I study looked at two additional clinical trial stratus. Stratum B of the clinical trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer. This explorative open-labeled Phase I study will evaluate the feasibility and safety of subcutaneous efti injections combined with either standard of care therapy of BAVENCIO®(or avelumab, PD-L1 inhibitor) in patients with advanced-staged solid tumors.
The study’s sponsor is the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IFK).
Dr. Daniel Wilhelm Mueller, PhD